<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01447485</url>
  </required_header>
  <id_info>
    <org_study_id>CVAL489K1101</org_study_id>
    <nct_id>NCT01447485</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients</brief_title>
  <official_title>A Multicenter, Open-label, Single-dose Study to Evaluate the Pharmacokinetics of Valsartan in Japanese Pediatric Patients 6 to 14 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetics and safety following single dose of valsartan in
      Japanese pediatric patients with hypertension, chronic kidney disease, or nephrotic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of valsartan in plasma</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of valsartan in plasma</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of valsartan in plasma</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of valsartan in plasma</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of valsartan in plasma</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ECG evaluations</measure>
    <time_frame>24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard clinical laboratory evaluations</measure>
    <time_frame>24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>2, 4, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hypertension</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Valsartan 20 mg or 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan (VAL489)</intervention_name>
    <arm_group_label>Valsartan 20 mg or 40 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese pediatric patients with hypertension, chronic kidney disease, or nephrotic
             syndrome

        Exclusion Criteria:

          -  GFR &lt; 30 mL/min/1.73 m2

          -  Inability to safely tolerate the temporary discontinuation of concomitant
             antihypertensive medications (expect amlodipine or atenolol) from 24 hours prior to
             study drug administration to study completion.

          -  Inability to safely tolerate the temporary discontinuation of any drug known or
             suspected to effect hepatic or renal clearance capacity from 24 hours prior to study
             drug administration to study completion (this includes drugs that are known to cause
             induction or inhibition of hepatic enzymes).

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2011</study_first_posted>
  <last_update_submitted>May 6, 2012</last_update_submitted>
  <last_update_submitted_qc>May 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension, chronic kidney disease</keyword>
  <keyword>nephrotic syndrome</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

